Background: Glabellar lines have social and psychological implication since oftentimes generate negative facial expressions that could be misunderstood, such as anger, anxiety, fear or sadness, and others related to extrinsic aging signs. Botulinum toxin type A has been used for more than 20 years in aesthetic medicine and one of many options to improve dynamic facial lines on upper third of the face, including glabellar lines. On April 2009. FDA approved abobotulinum toksin A (Dysport) as the latest botulinum toxin type A, a purified complex diluted with human serum albumin and lactose. Aim: The purpose of this study is to analyze the effectiveness of botulinum toxin type A (abobotulinum toxin A) as a therapy for moderate to severe glabellar lines. Methods: searching the electronic database Pubmed-MEDLINE, Scopus, ProQuest, Cochrane library, ClinicalTrials.gov, and Google Scholar, found five articles (n=1.134) included in qualitative and quantitave analysis. Result: Metaanalysis showed the value of Q statistic was z value = 9,079 (p=0,000). Glabellar lines improvement according to Glabellar Lines Scale were more prominent in botulinum toxin type A injection group compared to control group on the 30th day after botulinum toxin type A injection (relative risk 23,007; CI 95%,11,692 -45,274). The result of the overall metanalysis showed that glabellar lines severity in the group with botulinum toxin type A injection was significantly improved compared to control group. Conclusion: Botulinum toxin type A 50 U (abobotulinum toxin type A) is effective in significantly improving glabellar lines severity compared to placebo group .